Status:

COMPLETED

A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme

Lead Sponsor:

Eli Lilly and Company

Conditions:

Weight Gain

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weig...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • All patients, previously treated with olanzapine as antipsychotic monotherapy, which have shown a weight gain with an increase of BMI \>7% (assessed during the routine visits from the beginning of antipsychotic treatment).
  • Male or female subjects at least 18 and no more than 65 years of age.
  • Subjects must be considered reliable.
  • Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol.
  • Each patient, (and a patient's legal representative if mandated by local law), must understand the nature of the study and must sign an informed consent document.
  • Exclusion criteria:
  • Serious, unstable illnesses such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months. This includes hepatic (specifically any degree of jaundice), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic diseases (specifically current agranulocytosis with an absolute neutrophil count \<500 mm3).
  • Prior treatment with any antipsychotic drugs associated to olanzapine.
  • Judged clinically to be at significant suicidal or homicidal risk and/or agitated enough to necessitate use of restraints.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2003

    Trial Type :

    INTERVENTIONAL

    End Date :

    August 1 2005

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT00191828

    Start Date

    March 1 2003

    End Date

    August 1 2005

    Last Update

    January 26 2007

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speack with your personal physician.

    Sesto Fiorentino, Florence, Italy